Financial Performance - The company's revenue for Q3 2021 reached ¥100,582,552, representing an increase of 83.18% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥32,352,658.58, a significant increase of 155.13% year-over-year[3]. - The net profit excluding non-recurring gains and losses was ¥29,166,302.65, up 206.59% from the previous year[3]. - The basic earnings per share (EPS) was ¥0.0807, reflecting a growth of 129.26% compared to the same quarter last year[3]. - The company achieved operating revenue of CNY 431.07 million for the first three quarters of 2021, representing a year-on-year growth of 131.15%[14]. - The net profit attributable to shareholders reached CNY 195.66 million, a year-on-year increase of 277.03%[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 178.01 million, up 295.30% year-on-year[14]. - Total operating revenue for Q3 2021 reached ¥431,072,994.36, a significant increase of 131.3% compared to ¥186,494,430.62 in Q3 2020[21]. - Operating profit for Q3 2021 was ¥224,027,270.13, up from ¥58,981,752.58 in the same period last year, reflecting a growth of 278.5%[22]. - Net profit for Q3 2021 amounted to ¥195,631,959.45, compared to ¥51,909,188.28 in Q3 2020, representing an increase of 276.5%[22]. - The total comprehensive income for the period was CNY 194,894,966.29, compared to CNY 51,816,554.12 in Q3 2020, marking an increase of about 275.5%[23]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,107,073,439.24, an increase of 69.57% from the end of the previous year[3]. - Total current assets as of September 30, 2021, were ¥896,503,395.57, up from ¥526,129,020.88 at the end of 2020, indicating a growth of 70.3%[18]. - Total assets reached ¥1,107,073,439.24 as of September 30, 2021, compared to ¥652,886,483.47 at the end of 2020, marking an increase of 69.5%[19]. - Total liabilities increased to ¥205,909,931.81 in Q3 2021 from ¥103,903,179.01 in Q3 2020, reflecting a growth of 97.8%[19]. - Total liabilities reached CNY 103,903,179.01, with non-current liabilities at CNY 25,783,875.37[30]. - Current liabilities totaled CNY 78,119,303.64, with accounts payable at CNY 14,644,174.02[29]. - The total liabilities and owner's equity combined amounted to CNY 652,886,483.47[30]. Cash Flow - Cash flow from operating activities for the year-to-date reached ¥200,984,268.99, showing a remarkable increase of 417.19%[3]. - Net cash flow from operating activities was CNY 200,984,268.99, compared to CNY 38,861,074.17 in Q3 2020, indicating a growth of over 416%[26]. - The company reported a net cash outflow from investing activities of CNY -488,920,887.28, compared to CNY -354,702,861.41 in the same period last year[26]. - Cash inflow from financing activities was CNY 195,740,100.00, significantly higher than CNY 22,000,000.00 in Q3 2020[26]. - The company paid CNY 18,038,700.00 in dividends and interest, down from CNY 45,354,479.33 in the previous year[26]. Research and Development - Research and development expenses for Q3 2021 were ¥45,738,147.09, compared to ¥30,478,620.64 in Q3 2020, an increase of 50.0%[22]. - The company added 6 new authorized patents during the reporting period, including 1 invention patent[15]. Regulatory and Compliance - The company participated in the formulation of the national standard for "Immunochromatographic Test Strip Detection General Principles," which was approved and published[15]. - The company obtained a Class III medical device registration certificate for the HIV antibody test kit (colloidal gold method) in domestic registration[15]. - The company secured over 40 new EU CE certifications for international registration during the reporting period[15]. - The company has implemented new leasing standards affecting the financial statements, indicating a proactive approach to compliance and financial management[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,707[10]. - The company launched a restricted stock incentive plan draft in 2021 to enhance its incentive mechanism and support high-quality development[15]. - The company was included in the third batch of "specialized and innovative" small giant enterprises by the Ministry of Industry and Information Technology, indicating recognition of its advanced technology and business expansion[14]. Other Financial Metrics - The weighted average return on equity (ROE) improved to 3.65%, an increase of 1.25% year-over-year[3]. - The company reported a decrease in other comprehensive income, with a net amount of -¥766,404.59 in Q3 2021 compared to -¥78,983.41 in Q3 2020[22]. - The company recognized a right-of-use asset increase of CNY 44,711,437.99 due to the new leasing standard[30]. - The report for the third quarter was not audited[31].

Financial Performance - The company's revenue for the reporting period reached ¥330,490,442.36, representing a 151.16% increase compared to ¥131,586,778.83 in the same period last year[22]. - Net profit attributable to shareholders was ¥163,308,712.30, a significant increase of 316.45% from ¥39,214,478.51 in the previous year[22]. - The net cash flow from operating activities was ¥186,855,394.45, showing a remarkable increase of 5,216.83% compared to a negative cash flow of ¥3,651,781.73 in the same period last year[22]. - Basic earnings per share increased to ¥0.42, up 281.82% from ¥0.11 in the previous year[23]. - Total assets at the end of the reporting period were ¥1,088,282,961.78, a 66.69% increase from ¥652,886,483.47 at the end of the previous year[23]. - The net assets attributable to shareholders increased to ¥869,133,460.58, reflecting a growth of 58.30% from ¥549,053,562.88 at the end of the previous year[23]. - Operating profit surged to ¥182,792,891.81, reflecting a 301.21% increase from ¥45,560,011.97 in the prior year, attributed to the overall revenue growth[67]. - The company's net profit for the first half of 2021 was CNY 166,351,744.17, a significant increase from CNY 41,187,012.13 in the same period of 2020, representing a growth of 303.5%[188]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the CEO and accounting head[3]. - All board members attended the meeting to review the report, ensuring comprehensive oversight[4]. - The report includes a section on corporate governance, highlighting the company's commitment to transparency and accountability[7]. - The company completed its registration changes and obtained a new business license on April 12, 2021, following a series of corporate governance updates[21]. Strategic Developments - The company has outlined its future plans and strategic developments, although these do not constitute a commitment to investors[4]. - The company is advancing the registration of over 40 in vitro diagnostic products, with 16 new CE certifications obtained[36]. - The company is implementing a localized strategy for overseas sales to better serve local customers[36]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth momentum[182]. Research and Development - The company invested 30.18 million yuan in R&D, representing a 60.13% increase year-on-year[34]. - The company launched 76 new products, including a multi-residue rapid test strip for pesticide residues[34]. - The company has developed new technologies for animal testing, including multi-detection products for various diseases, which are expected to become new profit growth points[38]. - Research and development investment rose by 60.13% to ¥30,179,783.86, up from ¥18,847,467.83, highlighting the company's commitment to innovation[67]. Market Expansion - The company expanded its international market presence, covering over 60 countries and regions[36]. - The company established a marketing network covering over 60 countries, including Russia, France, and Italy, enhancing its market expansion capabilities[64]. - The company has developed customized products to meet diverse customer needs, enhancing sales through technological advantages[48]. Financial Management - The company raised a net amount of 175.35 million CNY from its IPO on the Shenzhen Stock Exchange in February 2021, marking a new phase of "industry + capital" development[39]. - The company has cash management of RMB 100 million from idle raised funds, with the remainder stored in a dedicated account[90]. - The company reported a total cash outflow from investing activities of ¥698,029,744.80, up from ¥514,350,490.66 in the previous period, indicating increased capital expenditures[195]. Compliance and Risk Management - The company is actively monitoring industry policies to mitigate risks associated with regulatory changes in the food safety testing sector[100]. - The company emphasizes the importance of compliance with local regulations for its products in international markets[101]. - The company faces risks related to reliance on imported raw materials, particularly nitrocellulose membranes, which are essential for its immunochromatographic testing products[105]. Shareholder Information - The company successfully completed its initial public offering, issuing 40.86 million shares, with trading commencing on February 9, 2021[144]. - The total number of ordinary shareholders at the end of the reporting period is 25,066[160]. - Shenzhen Yirui Holdings Co., Ltd. holds 37.67% of shares, totaling 151,001,310 shares, with no changes during the reporting period[160]. Environmental and Social Responsibility - The company does not belong to the key pollutant discharge units and has not faced any environmental penalties during the reporting period[117]. - There were no significant social responsibility initiatives reported during the period, such as poverty alleviation or rural revitalization efforts[118].

Financial Performance - The company's revenue for Q1 2021 was ¥146,917,926.77, representing a 103.46% increase compared to ¥72,209,692.72 in the same period last year[7] - Net profit attributable to shareholders for Q1 2021 was ¥87,610,355.16, a 150.10% increase from ¥35,030,572.53 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥79,440,063.33, up 133.33% from ¥34,045,540.77 in the previous year[7] - The basic earnings per share for Q1 2021 was ¥0.23, reflecting a 155.56% increase from ¥0.09 in the same quarter last year[7] - The company reported a net profit of CNY 89,853,820.63 for the quarter, reflecting strong operational performance[47] - The net profit for Q1 2021 reached CNY 87,599,429.10, up from CNY 35,021,960.21 in the same period last year, representing a growth of approximately 150%[48] - The total comprehensive income for Q1 2021 was CNY 86,965,485.64, compared to CNY 35,300,634.11 in the prior year, showing a growth of about 146%[49] Assets and Liabilities - The total assets at the end of the reporting period were ¥998,848,324.21, a 52.99% increase from ¥652,886,483.47 at the end of the previous year[7] - The total assets of the company reached CNY 998.85 million, up from CNY 652.89 million at the end of 2020, indicating a growth of 52.8%[39] - Total liabilities rose to CNY 176,648,028.56, compared to CNY 103,348,477.74 in the previous period[44] - Total current liabilities stand at CNY 77,564,602.37, showing a stable short-term financial position[67] Cash Flow - The net cash flow from operating activities was ¥98,176,735.85, a significant recovery from a negative cash flow of -¥20,689,163.91 in the same period last year[7] - Cash flow from operating activities was CNY 168,141,233.13, significantly higher than CNY 68,922,745.94 in the same period last year, demonstrating improved cash generation[55] - The net cash flow from financing activities was ¥182,706,115.09, a substantial increase from ¥21,997,320.65 in the previous year, highlighting successful fundraising efforts[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,501[10] - The largest shareholder, Shenzhen Yirui Holdings Co., Ltd., held 37.67% of the shares, amounting to 151,001,310 shares[10] Research and Development - R&D investment totaled 10.69 million yuan, up 27.73% from the same period last year, accounting for 7.28% of total revenue[19] - Research and development expenses for Q1 2021 amounted to CNY 10,690,252.58, compared to CNY 8,247,570.76 in the previous year, indicating an increase in investment in innovation[51] Government Subsidies and Other Income - The company received government subsidies amounting to ¥9,595,211.92 during the reporting period[8] - The company achieved a 210.57% increase in other income, totaling ¥3,595,211.92, primarily due to increased government subsidies[18] Inventory and Accounts Receivable - The company reported a significant increase in accounts receivable, rising by 745.11% to ¥2,693,583.00 due to an increase in bank acceptance bills received[17] - Inventory increased by 42.94% to ¥88,038,529.64, reflecting the company's growth in revenue and stock preparation[17] Market Presence and Future Plans - The company plans to expand its production capacity, leading to an increase in non-current assets by 98.97% to ¥13,550,104.77[17] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[47] Compliance and Governance - The company has undergone a board and supervisory committee restructuring, with new members elected in March 2021[26] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[33]

Financial Performance - The company's operating revenue for 2020 was CNY 258,455,671.51, an increase of 8.06% compared to CNY 239,178,001.68 in 2019[19]. - The net profit attributable to shareholders for 2020 was CNY 65,445,058.17, a decrease of 29.10% from CNY 92,308,448.82 in 2019[19]. - The net profit after deducting non-recurring gains and losses was CNY 56,877,824.49, down 24.89% from CNY 75,722,397.27 in 2019[19]. - The basic earnings per share for 2020 was CNY 0.18, a decline of 30.77% compared to CNY 0.26 in 2019[19]. - The total assets at the end of 2020 were CNY 652,886,483.47, representing a 5.36% increase from CNY 619,665,211.31 at the end of 2019[19]. - The net assets attributable to shareholders at the end of 2020 were CNY 549,053,562.88, an increase of 3.91% from CNY 528,394,104.82 at the end of 2019[19]. - The cash flow from operating activities for 2020 was CNY 63,793,860.76, a decrease of 5.13% from CNY 67,243,603.60 in 2019[19]. - The weighted average return on equity for 2020 was 12.32%, down from 19.62% in 2019, a decrease of 7.30%[19]. - The company reported a decrease in operating profit to 75.11 million yuan, down 28.63% year-on-year[57]. - The company achieved total operating revenue of 258.46 million yuan in 2020, an increase of 8.06% compared to the previous year[57]. Dividend Distribution - The company plans to distribute a cash dividend of 0.45 RMB per 10 shares based on a total share capital of 400,860,000 shares as of March 31, 2021[5]. - The cash dividend represents 100% of the total profit distribution amount for the year[114]. - The cash dividend payout ratio for 2020 is 27.56% of the net profit attributable to the parent company[118]. - The company did not issue any bonus shares or increase capital from reserves during the reporting period[116]. - The independent directors confirmed their agreement with the dividend distribution plan[115]. Business Strategy and Market Position - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge[7]. - The report covers the operational performance and future outlook, detailing the company's strategic direction and potential challenges[5]. - The company has outlined its business overview and key financial indicators in the annual report, providing insights into its market position[7]. - The company aims to deepen its focus on food safety rapid testing while expanding into POCT and animal disease detection, creating an integrated detection ecosystem[102]. - The company plans to develop high-end technology products such as portable mass spectrometers and biosensors, maintaining its R&D capabilities and technological advantages[103]. Research and Development - The company has invested significantly in R&D, focusing on technology innovation and product development to maintain its competitive edge[51]. - The company invested 40.46 million yuan in R&D during the reporting period, representing a year-on-year increase of 20.12% and accounting for 15.66% of total revenue, ensuring continuous output of R&D results[60]. - The company has developed over 400 high-precision rapid testing reagents, focusing on detecting pesticide residues, veterinary drug residues, and pathogenic microorganisms[30]. - The company has established a robust R&D model combining independent research and technical cooperation, focusing on market-driven needs and cutting-edge technology[32]. - The company has developed five major technology platforms in the in vitro diagnostic business, completing over 70 product developments across three major product series: drug detection, infectious disease detection, and chronic disease management[63]. Operational Challenges and Risks - The company acknowledges the uncertainty and potential unsustainability of revenue growth from COVID-19 related products, which depends on various external factors[109]. - The company faces risks related to policy changes that could impact its operations and the food safety testing industry, necessitating timely adjustments to its business strategies[108]. - The rapid expansion of the company's operations into new business areas may lead to management challenges if the management team and systems do not keep pace with growth[110]. - The company is reliant on imported raw materials, particularly nitrocellulose membranes, which poses a risk to production costs and supply stability[109]. Governance and Compliance - The company has outlined its governance structure and shareholder information, emphasizing transparency and compliance with regulatory requirements[7]. - The report indicates that all board members attended the meeting to review the annual report, ensuring collective accountability[4]. - The company emphasizes the protection of shareholder and creditor rights, adhering to relevant laws and regulations[142]. - The independent directors attended all 9 board meetings and 6 shareholder meetings during the reporting period[196]. - The company maintains a structured approach to governance through its various committees[200]. Market Trends and Growth Opportunities - The global food safety testing market is projected to grow from $12.01 billion in 2016 to $18.54 billion by 2022, with a compound annual growth rate (CAGR) of approximately 7.6%[39]. - The global food rapid testing market is expected to increase from $10.14 billion in 2016 to $15.71 billion by 2022, accounting for about 85% of the total food safety testing market[40]. - The domestic food safety rapid testing market size was approximately RMB 2.977 billion in 2017, with a projected compound annual growth rate (CAGR) of 25.24% from 2017 to 2022, reaching RMB 9.175 billion by 2022[42]. - The company is diversifying into in vitro diagnostics and animal disease businesses, which are expected to provide new growth points for performance[39]. - The company has successfully developed testing products for African swine fever, foot-and-mouth disease, and other animal diseases, with plans to accelerate the layout of its animal disease testing business to capture new profit growth points[106]. Employee and Management Structure - The company employed a total of 476 staff, including 180 production personnel and 133 R&D personnel[184]. - The educational background of employees includes 8 with PhDs, 20 with master's degrees, and 199 with bachelor's degrees[184]. - The company has established a scientific compensation performance system to enhance employee performance and competitiveness[185]. - The total remuneration for directors and senior management in 2020 amounted to RMB 3.7477 million[181]. - The company has a diverse professional composition, with 76 sales personnel and 48 management personnel[184]. Environmental and Social Responsibility - The company has passed the ISO 14001:2015 environmental management system certification, emphasizing its commitment to sustainable development[148]. - The company has actively supported government food safety projects, enhancing the detection capabilities of food regulatory departments[148]. - The company has not reported any significant environmental pollution during its production processes[148]. - The company plans to continue its focus on health and environmental protection in its operations[148].